$5.43
0.93% yesterday
Nasdaq, Jun 30, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Target price 2025 - Analyst rating & recommendation

CureVac N.V. Classifications & Recommendation:

Buy
69%
Hold
23%
Sell
8%

CureVac N.V. Price Target

Target Price $4.34
Price $5.43
Deviation
Number of Estimates 8
8 Analysts have issued a price target CureVac N.V. 2026 . The average CureVac N.V. target price is $4.34. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 9 Analysts recommend CureVac N.V. to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CureVac N.V. stock has an average upside potential 2026 of . Most analysts recommend the CureVac N.V. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 630.52 82.52
895.61% 86.84%
EBITDA Margin 36.83% -124.37%
107.97% 437.72%
Net Margin 30.31% -172.89%
106.26% 670.50%

10 Analysts have issued a sales forecast CureVac N.V. 2025 . The average CureVac N.V. sales estimate is

$82.5m
Unlock
. This is
86.56% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$157m 74.50%
Unlock
, the lowest is
$1.0m 99.83%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $631m 895.61%
2025
$82.5m 86.84%
Unlock
2026
$102m 24.04%
Unlock
2027
$168m 64.16%
Unlock
2028
$234m 38.98%
Unlock
2029
$299m 28.15%
Unlock
2030
$346m 15.74%
Unlock
2031
$355m 2.63%
Unlock
2032
$230m 35.41%
Unlock

7 Analysts have issued an CureVac N.V. EBITDA forecast 2025. The average CureVac N.V. EBITDA estimate is

$-103m
Unlock
. This is
140.46% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-58.9m 123.24%
Unlock
, the lowest is
$-173m 168.09%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $232m 179.31%
2025
$-103m 144.43%
Unlock
2026
$-107m 4.07%
Unlock
2027
$-32.1m 69.94%
Unlock
2028
$-152m 373.78%
Unlock

EBITDA Margin

2024 36.83% 107.97%
2025
-124.37% 437.72%
Unlock
2026
-104.35% 16.10%
Unlock
2027
-19.11% 81.69%
Unlock

9 CureVac N.V. Analysts have issued a net profit forecast 2025. The average CureVac N.V. net profit estimate is

$-143m
Unlock
. This is
167.38% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-72.0m 134.02%
Unlock
, the lowest is
$-191m 190.38%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $191m 162.34%
2025
$-143m 175.05%
Unlock
2026
$-135m 5.03%
Unlock
2027
$-70.9m 47.69%
Unlock

Net Margin

2024 30.31% 106.26%
2025
-172.89% 670.50%
Unlock
2026
-132.37% 23.44%
Unlock
2027
-42.19% 68.13%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.85 -0.63
161.15% 175.00%
P/E negative
EV/Sales 8.93

9 Analysts have issued a CureVac N.V. forecast for earnings per share. The average CureVac N.V. EPS is

$-0.63
Unlock
. This is
167.02% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.32 134.04%
Unlock
, the lowest is
$-0.85 190.43%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.85 161.15%
2025
$-0.63 175.00%
Unlock
2026
$-0.60 4.76%
Unlock
2027
$-0.31 48.33%
Unlock

P/E ratio

Current 5.72 342.28%
2025
-8.49 248.34%
Unlock
2026
-8.94 5.30%
Unlock
2027
-17.09 91.16%
Unlock

Based on analysts' sales estimates for 2025, the CureVac N.V. stock is valued at an EV/Sales of

and an P/S ratio of
14.68
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.20 81.31%
2025
8.93 644.37%
Unlock
2026
7.20 19.38%
Unlock
2027
4.39 39.08%
Unlock
2028
3.16 28.05%
Unlock
2029
2.46 21.96%
Unlock
2030
2.13 13.60%
Unlock
2031
2.07 2.57%
Unlock
2032
3.21 54.82%
Unlock

P/S ratio

Current 1.97 81.86%
2025
14.68 643.85%
Unlock
2026
11.84 19.38%
Unlock
2027
7.21 39.08%
Unlock
2028
5.19 28.05%
Unlock
2029
4.05 21.97%
Unlock
2030
3.50 13.60%
Unlock
2031
3.41 2.57%
Unlock
2032
5.28 54.82%
Unlock

Current CureVac N.V. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
UBS
Locked
Locked
Locked Jun 26 2025
Jefferies
Locked
Locked
Locked Jun 13 2025
JMP Securities
Locked
Locked
Locked May 28 2025
UBS
Locked
Locked
Locked Apr 30 2025
JMP Securities
Locked
Locked
Locked Feb 14 2025
JMP Securities
Locked
Locked
Locked Sep 16 2024
Analyst Rating Date
Locked
UBS:
Locked
Locked
Jun 26 2025
Locked
Jefferies:
Locked
Locked
Jun 13 2025
Locked
JMP Securities:
Locked
Locked
May 28 2025
Locked
UBS:
Locked
Locked
Apr 30 2025
Locked
JMP Securities:
Locked
Locked
Feb 14 2025
Locked
JMP Securities:
Locked
Locked
Sep 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today